Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15741160 | 1.00 | FFAR3 (0.39) | FFAR3 | |
| SCHEMBL15741165 | 0.82 | MEN1 (0.32) | — | |
| SCHEMBL15741176 | 0.82 | MEN1 (0.32) | — | |
| SCHEMBL15741022 | 0.82 | MEN1 (0.32) | — | |
| SCHEMBL15748068 | 0.77 | — | — | |
| SCHEMBL17192506 | 0.74 | FFAR3 (0.32) | FFAR3 | |
| SCHEMBL24004769 | 0.74 | FFAR3 (0.45) | FFAR3 | |
| SCHEMBL23897414 | 0.74 | FFAR3 (0.45) | FFAR3 | |
| SCHEMBL24004674 | 0.74 | FFAR3 (0.45) | FFAR3 | |
| SCHEMBL31324041 | 0.74 | FFAR3 (0.45) | FFAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4245744-A2 | CHEMICALLY CLEAVABLE GROUP | Tagworks Pharmaceuticals B.V. (NL) | 2023-09-20 | — | — | EP | disclosed |
| EP-2922574-B1 | CHEMICALLY CLEAVABLE GROUP | TAGWORKS PHARMACEUTICALS B V (NL) | 2023-05-17 | — | — | EP | disclosed |
| US-20150344514-A1 | CHEMICALLY CLEAVABLE GROUP | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2015-12-03 | — | — | US | disclosed |
| US-20150297741-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2015-10-22 | — | — | US | disclosed |
| WO-2014081303-A1 | CHEMICALLY CLEAVABLE GROUP | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2014-05-30 | — | — | WO | disclosed |
| WO-2014081300-A1 | CHANNEL PROTEIN ACTIVATABLE LIPOSOMES | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2014-05-30 | — | — | WO | disclosed |
| WO-2014081299-A1 | ACTIVATABLE LIPOSOMES | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2014-05-30 | — | — | WO | disclosed |
| WO-2014081301-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2014-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344514-A1 | CHEMICALLY CLEAVABLE GROUP | SQLE, CTRL, ENO1 | FFAR3 3639/4885 |
| US-20150297741-A1 | BIO-ORTHOGONAL DRUG ACTIVATION | KIT, JMJD7, TPSB2 | FFAR3 1135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.